190 related articles for article (PubMed ID: 26075443)
21. Endoglin (CD105) expression in neurofibromatosis type 2 vestibular schwannoma.
Marioni G; Nicolè L; Cazzador D; Pavone C; D'Avella D; Martini A; Mazzoni A; Zanoletti E
Head Neck; 2019 Oct; 41(10):3612-3617. PubMed ID: 31313389
[TBL] [Abstract][Full Text] [Related]
22. A non-NF2 case of schwannomas of vestibular and trigeminal nerves with different genetic alterations of NF2 gene: case report.
Kambe A; Kamitani H; Watanabe T; Oka A; Inagaki H; Ishii T; Ueki K
Surg Neurol; 2005 Jan; 63(1):62-4; discussion 64-5. PubMed ID: 15639530
[TBL] [Abstract][Full Text] [Related]
23. ErbB and Nrg: potential molecular targets for vestibular schwannoma pharmacotherapy.
Doherty JK; Ongkeko W; Crawley B; Andalibi A; Ryan AF
Otol Neurotol; 2008 Jan; 29(1):50-7. PubMed ID: 18199957
[TBL] [Abstract][Full Text] [Related]
24. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas.
Mohyuddin A; Neary WJ; Wallace A; Wu CL; Purcell S; Reid H; Ramsden RT; Read A; Black G; Evans DG
J Med Genet; 2002 May; 39(5):315-22. PubMed ID: 12011146
[TBL] [Abstract][Full Text] [Related]
25. [Neurotrophic factor expression in vestibular schwannoma. An overview].
Diensthuber M; Lenarz T; Stöver T
Laryngorhinootologie; 2006 Oct; 85(10):731-7. PubMed ID: 16612755
[TBL] [Abstract][Full Text] [Related]
26. [Neurofibromatosis type 2 (central neurofibromatosis or bilateral acoustic neuromas, vestibular schwannomas): from phenotype to gene].
Sabol Z; Kipke-Sabol L; Miklić P; Hajnsek-Propadalo S; Sabol F
Lijec Vjesn; 2006; 128(9-10):309-16. PubMed ID: 17128670
[TBL] [Abstract][Full Text] [Related]
27. Genesis and biology of vestibular schwannomas.
Roche PH; Bouvier C; Chinot O; Figarella-Branger D
Prog Neurol Surg; 2008; 21():24-31. PubMed ID: 18810196
[TBL] [Abstract][Full Text] [Related]
28. The microenvironment in sporadic and neurofibromatosis type II-related vestibular schwannoma: the same tumor or different? A comparative imaging and neuropathology study.
Lewis D; Donofrio CA; O'Leary C; Li KL; Zhu X; Williams R; Djoukhadar I; Agushi E; Hannan CJ; Stapleton E; Lloyd SK; Freeman SR; Wadeson A; Rutherford SA; Hammerbeck-Ward C; Evans DG; Jackson A; Pathmanaban ON; Roncaroli F; King AT; Coope DJ
J Neurosurg; 2020 May; 134(5):1419-1429. PubMed ID: 32470937
[TBL] [Abstract][Full Text] [Related]
29. The comparison between the growth fraction of bilateral vestibular schwannomas in neurofibromatosis 2 (NF2) and unilateral vestibular schwannomas using the monoclonal antibody MIB 1.
Aguiar PH; Tatagiba M; Samii M; Dankoweit-Timpe E; Ostertag H
Acta Neurochir (Wien); 1995; 134(1-2):40-5. PubMed ID: 7668124
[TBL] [Abstract][Full Text] [Related]
30. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects.
Slattery WH; Fisher LM; Iqbal Z; Oppenhiemer M
Otol Neurotol; 2004 Sep; 25(5):811-7. PubMed ID: 15354016
[TBL] [Abstract][Full Text] [Related]
31. Identification of recurrent regions of chromosome loss and gain in vestibular schwannomas using comparative genomic hybridisation.
Warren C; James LA; Ramsden RT; Wallace A; Baser ME; Varley JM; Evans DG
J Med Genet; 2003 Nov; 40(11):802-6. PubMed ID: 14627667
[TBL] [Abstract][Full Text] [Related]
32. Microarray analysis of gene expression in vestibular schwannomas reveals SPP1/MET signaling pathway and androgen receptor deregulation.
Torres-Martin M; Lassaletta L; San-Roman-Montero J; De Campos JM; Isla A; Gavilan J; Melendez B; Pinto GR; Burbano RR; Castresana JS; Rey JA
Int J Oncol; 2013 Mar; 42(3):848-62. PubMed ID: 23354516
[TBL] [Abstract][Full Text] [Related]
33. Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2.
Li H; Hao SY; Wang L; Li D; Wu Z; Zhang LW; Zhang JT
Acta Neurochir (Wien); 2015 Nov; 157(11):1983-90. PubMed ID: 26287269
[TBL] [Abstract][Full Text] [Related]
34. [Pathogenesis and molecular pathology of vestibular schwannoma].
Brodhun M; Stahn V; Harder A
HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
[TBL] [Abstract][Full Text] [Related]
35. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
36. [Type 2 neurofibromatosis without acoustic neuroma].
Mautner VF; Lindenau M; Köppen J; Hazim W; Kluwe L
Zentralbl Neurochir; 1995; 56(2):83-7. PubMed ID: 7639047
[TBL] [Abstract][Full Text] [Related]
37. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors.
Dirks MS; Butman JA; Kim HJ; Wu T; Morgan K; Tran AP; Lonser RR; Asthagiri AR
J Neurosurg; 2012 Jul; 117(1):109-17. PubMed ID: 22503123
[TBL] [Abstract][Full Text] [Related]
38. Next Generation Sequencing of Sporadic Vestibular Schwannoma: Necessity of Biallelic NF2 Inactivation and Implications of Accessory Non-NF2 Variants.
Carlson ML; Smadbeck JB; Link MJ; Klee EW; Vasmatzis G; Schimmenti LA
Otol Neurotol; 2018 Oct; 39(9):e860-e871. PubMed ID: 30106846
[TBL] [Abstract][Full Text] [Related]
39. Lack of neurofibromatosis type 2 gene promoter methylation in sporadic vestibular schwannomas.
Koutsimpelas D; Ruerup G; Mann WJ; Brieger J
ORL J Otorhinolaryngol Relat Spec; 2012; 74(1):33-7. PubMed ID: 22249120
[TBL] [Abstract][Full Text] [Related]
40. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.
Ouerdani A; Goutagny S; Kalamarides M; Trocóniz IF; Ribba B
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1263-73. PubMed ID: 27146400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
